Remsima approved in Colombia

Biosimilars/News | Posted 10/01/2014 post-comment0 Post your comment

On 16 December 2013, Colombia’s National Institute of Food and Drug Monitoring (INVIMA – Instituto Nacional de Vigilancia de Medicamentos Y Alimentos) announced the approval of Remsima (infliximab) – the first producto bioterapéutico similar (similar biotherapeutic product) to be approved in Colombia.

Remsima V14A10

South Korean biotechnology company Celltrion developed the biosimilar monoclonal antibody infliximab in collaboration with its partner Hospira. The two companies gained European approval for Remsima (Celltrion) and Inflectra (Hospira) in September 2013 [1].

The Colombian Ministry of Health and Social Protection (Ministerio de Salud y Protección Social de Colombia) released a new draft guideline for biologicals, including biosimilars, in January 2013 [2]. The guideline provides for a ‘comparability pathway’ that permits approval of a producto bioterapéutico similar based on a comparison to a reference biotherapeutic product.

The Colombian approval of Remsima has been granted to Amarey Nova Medical by INVIMA – the equivalent to US Food and Drug Administration – which comes under the Colombian Ministry of Health and Social Protection.  Remsima is approved in Colombia for the indications of rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis – the same as those covered by the European approval.

Colombia has the fourth smallest pharmaceutical market in the Latin America region. Despite this fact, in 2012, the pharmaceutical market was worth US$4.23 billion. The market value is also expected to increase due to the fact that Colombia is looking to increase drug access for the whole population under its universal insurance programme.

Editor’s comment
It should be noted that productos bioterapéuticos similares approved in Colombia might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the EU. EMA regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.

Related article

Similar biotherapeutic productsapproved and marketed in Latin America


1.  GaBI Online - Generics and Biosimilars Initiative. EC approves first monoclonal antibody biosimilar []. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jan 10]. Available from:

2.  GaBI Online - Generics and Biosimilars Initiative. Colombia issues draft decree for registration of biologicals []. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jan 10]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.

Source: INVIMA

comment icon Comments (0)
Post your comment
Related content
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010